Technology Facility STA Pharmaceutical Plans to Launch New Center in China

Author / Editor: Ahlam Rais / Wolfgang Ernhofer

The new facility will enable the company to introduce transition metal catalyst-screening technology to their existing manufacturing platform.

Related Vendors

STA Pharmaceutical has announced its plans to launch a new transition metal catalysis center at their integrated API process, R&D and manufacturing site in China.
STA Pharmaceutical has announced its plans to launch a new transition metal catalysis center at their integrated API process, R&D and manufacturing site in China.
(Source: Deposit Photos)

Shanghai/China — STA Pharmaceutical has recently announced its plans to launch a new transition metal catalysis center at their integrated API process, R&D and manufacturing site in Changzhou, China. The new state-of-the-art facility will allow the company to carry out rapid screening of metal catalysts, ligands, bases, acids, chemical resolving reagents, and amide formation coupling reagents, etc.

The screening kits will enable high-throughput screening of metal catalysts and ligands for C-C, C-N, C-O and C-S formation reactions, as well as many other types of reactions such as chemical resolution and amide formation. The technology allows the STA team to work effectively in finding the optimal catalysts by using a parallel interactive testing approach.

A team of scientists specialized in this technology are currently being trained at the company’s R&D center in Shanghai and once the new center becomes fully operational they will move to the Changzhou site.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:44968264)